Thiogenesis Therapeutics
Cambridge, United States· Est.
A private biotech leveraging engineered thiol prodrugs to treat mitochondrial and metabolic diseases with improved safety and efficacy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A private biotech leveraging engineered thiol prodrugs to treat mitochondrial and metabolic diseases with improved safety and efficacy.
Mitochondrial DiseasesMetabolic DiseasesRare Genetic Disorders
Technology Platform
Engineered cysteamine prodrugs (thiols) that release cysteamine gradually to boost intracellular cysteine, enhancing glutathione, taurine, and CoA production for improved redox balance.
Opportunities
Leverages the 505(b)(2) pathway for faster, lower‑cost development and addresses a high‑unmet‑need market in rare mitochondrial diseases and metabolic disorders.
Risk Factors
Clinical efficacy and safety in target pediatric populations remain uncertain; funding requirements for multi‑phase trials could strain cash runway.
Competitive Landscape
Competes with other mitochondrial therapeutics and cysteamine analogues, but differentiates through its prodrug design that improves tolerability and enables once‑daily dosing.